adjuvant Tecentriq
Natera to Present 14 Studies at ESMO, Including IMvigor011 Oral Presentation in Presidential Symposium
Natera; ESMO Congress; IMvigor011 trial; Presidential Symposium; Signatera; molecular residual disease; muscle-invasive bladder cancer; adjuvant Tecentriq; precision medicine; clinical oncology